Literature DB >> 20190100

Differential AMPK phosphorylation sites associated with phenylephrine vs. antihypertrophic effects of adenosine agonists in neonatal rat ventricular myocytes.

Theresa Pang1, Venkatesh Rajapurohitam, Michael A Cook, Morris Karmazyn.   

Abstract

Stimulation of cardiac AMP-activated protein kinase (AMPK) has been demonstrated in both prohypertrophic and antihypertrophic settings, although the reasons for such discrepant results are not well understood. We determined how AMPK is regulated in response to phenylephrine-induced cardiomyocyte hypertrophy and assessed whether AMPK activity may be a factor underlying the antihypertrophic effect of adenosine receptor agonists. The role of AMPK in hypertrophic responses was determined by assessing the effect of the AMPK activator 5-aminoimidazole-4-carboxyamide ribonucleoside on three hypertrophic indexes, including protein synthesis, cell surface area, and fetal gene expression. The changes in phosphorylation of the catalytic alpha-subunit of AMPK at two different sites, Thr(172) and Ser(485/491), in response to phenylephrine and adenosine receptor agonists were also examined. 5-Aminoimidazole-4-carboxyamide ribonucleoside completely abolished phenylephrine-induced increases in protein synthesis, cell surface area, and fetal gene expression. AMPK phosphorylation time course studies revealed that phenylephrine induced a time-dependent activation at site Ser(485/491), in contrast to adenosine receptor agonists, which demonstrated rapid AMPK phosphorylation at Thr(172). Furthermore, the phosphorylation at Ser(485/491) by phenylephrine was not affected by the addition of adenosine receptor agonists, although, conversely, phosphorylation of AMPK at Thr(172) by adenosine receptor agonists was abrogated by the addition of phenylephrine. We propose from these results that cardiomyocyte hypertrophic and antihypertrophic responses, at least with respect to inhibition of phenylephrine-induced hypertrophy by adenosine receptor agonists, are mediated by multisite AMPK regulation. The latter are reflected by increased phosphorylation at Ser(485/491) and at Thr(172), associated with prohypertrophic and antihypertrophic responses, respectively.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20190100     DOI: 10.1152/ajpheart.00424.2009

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  9 in total

Review 1.  Targeting the energy guardian AMPK: another avenue for treating cardiomyopathy?

Authors:  Tian Li; Shuai Jiang; Zhi Yang; Zhiqiang Ma; Wei Yi; Dongjin Wang; Yang Yang
Journal:  Cell Mol Life Sci       Date:  2016-11-04       Impact factor: 9.261

2.  Changes in AMPKα and Ubiquitin Ligases in Myocyte Reverse Remodeling after Surgical Ventricular Reconstruction in rats with ischemic cardiomyopathy.

Authors:  Yasushige Shingu; Tetsuya Hieda; Satoshi Sugimoto; Hidetsugu Asai; Tomoji Yamakawa; Satoru Wakasa
Journal:  Mol Biol Rep       Date:  2022-05-08       Impact factor: 2.742

3.  Prevention of RhoA activation and cofilin-mediated actin polymerization mediates the antihypertrophic effect of adenosine receptor agonists in angiotensin II- and endothelin-1-treated cardiomyocytes.

Authors:  Asad Zeidan; Xiaohong Tracey Gan; Ashley Thomas; Morris Karmazyn
Journal:  Mol Cell Biochem       Date:  2013-10-06       Impact factor: 3.396

Review 4.  Androgen-Regulated Cardiac Metabolism in Aging Men.

Authors:  Genaro Barrientos; Paola Llanos; Carla Basualto-Alarcón; Manuel Estrada
Journal:  Front Endocrinol (Lausanne)       Date:  2020-05-15       Impact factor: 5.555

5.  Testosterone activates glucose metabolism through AMPK and androgen signaling in cardiomyocyte hypertrophy.

Authors:  Mayarling Francisca Troncoso; Mario Pavez; Carlos Wilson; Daniel Lagos; Javier Duran; Sebastián Ramos; Genaro Barrientos; Patricio Silva; Paola Llanos; Carla Basualto-Alarcón; B Daan Westenbrink; Sergio Lavandero; Manuel Estrada
Journal:  Biol Res       Date:  2021-02-05       Impact factor: 5.612

6.  MicroRNA-150 and its target ETS-domain transcription factor 1 contribute to inflammation in diabetic photoreceptors.

Authors:  Fei Yu; Michael L Ko; Gladys Y-P Ko
Journal:  J Cell Mol Med       Date:  2021-10-26       Impact factor: 5.310

Review 7.  Targeting Adrenergic Receptors in Metabolic Therapies for Heart Failure.

Authors:  Dianne M Perez
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

Review 8.  Testosterone, cardiomyopathies, and heart failure: a narrative review.

Authors:  Rodica Diaconu; Ionuţ Donoiu; Oana Mirea; Tudor Adrian Bălşeanu
Journal:  Asian J Androl       Date:  2021 Jul-Aug       Impact factor: 3.285

9.  Cordycepin activates AMP-activated protein kinase (AMPK) via interaction with the γ1 subunit.

Authors:  Chongming Wu; Yanshen Guo; Yan Su; Xue Zhang; Hong Luan; Xiaopo Zhang; Huixin Zhu; Huixia He; Xiaoliang Wang; Guibo Sun; Xiaobo Sun; Peng Guo; Ping Zhu
Journal:  J Cell Mol Med       Date:  2013-11-28       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.